Serum glutamic acid decarboxylase 65 antibody levels in people with schizophrenia and their families. by Gaughran, F, Howes, O, Chrisman, L, Vincent, A

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. by Davies, L, Lewis, S, Jones, P, Barnes, T, Gaughran, F, Hayhurst, K, Markwick, A, Lloyd, H

A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. by Davies, L, Barnes, T, Jones, P, Lewis, S, Gaughran, F, Hayhurst, K, Markwick, A, Lloyd, H

Predictors of falls and fractures leading to hospitalization in people with schizophrenia spectrum disorder: A large representative cohort study by Stubbs, B, Mueller, C, Gaughran, F, Lally, J, Vancampfort, D, Lamb, S, Koyanagi, A, Sharma, S, Stewart, R, Perera, G

Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development by Pillinger, T, Howes, OD, Correll, CU, Leucht, S, Huhn, M, Schneider-Thoma, J, Gaughran, F, Jauhar, S, McGuire, PK, Taylor, DM, Young, AH, McCutcheon, RA